Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Melanoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibromatosis 1 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

AZD 6244 6trametinib 2talimogene laherparepvec 1omipalisib 1mirdametinib 1lorlatinib 1encorafenib 1dabrafenib 1binimetinib 1Specimen Handling 1Sirolimus 1Lasers, Solid-State 1Lasers 1Curcumin 1Cetuximab 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatosis 1 × omipalisib × 30 days × Clear all
NCT03190915 2026-05-27

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
10 enrolled 11 charts
CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡